Full text is available at the source.
Tirzepatide: A Review in Type 2 Diabetes
Tirzepatide and its use in type 2 diabetes
AI simplified
Abstract
Tirzepatide is approved for improving glycaemic control in adults with type 2 diabetes mellitus (T2DM).
- In phase III SURPASS trials, tirzepatide demonstrated superior efficacy in glycaemic control and weight loss compared to the GLP-1 receptor agonists dulaglutide and semaglutide, as well as insulin.
- Tirzepatide was generally well tolerated, showing a safety profile similar to that of GLP-1 receptor agonists.
- The treatment was associated with a low risk of clinically significant or severe hypoglycaemia and did not increase the risk of major adverse cardiovascular events.
- Common adverse events included mild to moderate gastrointestinal issues such as nausea, diarrhoea, decreased appetite, and vomiting.
AI simplified